Pfizer and Flagship Expand Collaboration to Tackle Obesity and Lung Cancer

Pfizer and Flagship Pioneering have strengthened their partnership by collaborating with two Flagship-founded companies, Ampersand Biomedicines and Montai Therapeutics, to develop innovative treatments for obesity and lung cancer, respectively. Ampersand is focusing on biologic medicines targeting tissue-specific metabolic pathways to improve metabolic health and tackle obesity, marking a reinvigorated attempt at addressing this critical health issue in their expanded agreement[1][2]. Meanwhile, Montai Therapeutics is utilizing its CONECTA platform to discover small molecule drugs that target cancer cell growth mechanisms in lung cancer. Both ventures fall under the broader scope of the "Pioneering Medicines" initiative, aiming to discover up to 10 new drugs, thereby leveraging the extensive research and resources from Flagship’s portfolio of startups[2].